Clinical trials: Drug-Drug Interactions, open to volunteers
Overweight, Obesity
Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin
The purpose of this study is to characterize the Influence of HDM1005 on gastric emptying and drug-drug interaction of HDM1005 and metformin, atorvastatin, warfarin, and digoxin in overweight/obese adult subjects.
- Trial name
- NCT07502001
- Testing
- Acetaminophen, Metformin, Warfarin
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Pharmacogenetics, Depression - Major Depressive Disorder
An Evaluation of the Impact of Pharmacist Comprehensive Medication Management With Pharmacogenomic Results to Improve Depression Outcomes in Community Pharmacies.
The goal of this prospective, randomized clinical trial is to learn whether pharmacogenomic (PGx)-guided comprehensive medication management delivered by pharmacists in community pharmacies will improve antidepressant treatment…
- Conditions
- Pharmacogenetics, Depression - Major Depressive Disorder, Pharmacogenomic Drug Interaction, Community Pharmacy Services
- Trial name
- COMPASS-PGx (NCT07373470)
- Testing
- Comprehensive medication management with PGx testing results, Usual Care
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- University of Pittsburgh
Pharmacogenomic Drug Interaction
Trial of Precision Medicine in Emergency Departments
The objectives of this study are to (1) test the feasibility of the clinical implementation of preemptive pharmacogenetic (PGx) testing in the emergency department (ED) and (2) determine if PGx testing (with appropriate decision…
- Trial name
- TOPMEDs (NCT06448091)
- Testing
- Panel-based pharmacogenetic genotyping
- Where
- 3 sites in United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- University of Florida
Refractory or Relapsed Solid Tumors
Phase I Study of QLC5508 in Advanced Solid Tumors: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction
A clinical trial of QLC5508 for advanced solid tumors The goal of this clinical trial is to learn if QLC5508 can be given safely to adults with advanced solid tumors.
- Trial name
- NCT07620041
- Testing
- QLC5508 (Investigational Product / Formulation T), QLC5508 (Reference Product / Formulation R), Itraconazole
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Aging, Adverse Drug Interaction
MinMed: Do Older Adults do Better With Less Medication
Many health care providers believe "less-is-more" for older adults, and evidence suggests minimizing certain medications might improve health outcomes.
- Conditions
- Aging, Adverse Drug Interaction, Frailty
- Trial name
- NCT05307666
- Testing
- Medication minimization
- Where
- Canada
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- University of Alberta
Steatohepatitis, Nonalcoholic, Osteo Arthritis
DDI Study of ECC0509 With Metformin, Midazolam, and Caffeine
This is a Phase 1, open-label, 2-part, fixed-sequence, single-center, two-period, drug-drug interaction trial in healthy adult participants to determine if ECC0509 administration at steady state affects the pharmacokinetics (PK)…
- Trial name
- NCT07873229
- Testing
- ECC0509, Metformin, Caffeine
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eccogene
Ulcerative Colitis, Crohn's Disease
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
This is an open-label, single group, 2-period, Phase 1, single-arm study. The primary purpose of this study is to investigate the effects of duvakitug on the pharmacokinetics of selected cytochrome P450 substrates in adult…
- Trial name
- NCT07923383
- Testing
- Duvakitug
- Volunteers
- 25 people
- Sponsor
- Sanofi
Drug Drug Interaction (DDI)
Study on the Drug Interaction Between Buagafuran and Voriconazole
This study is a non-randomized, open label trial aimed at evaluating the drug interaction between Buagafuran capsules and voriconazole tablets in Chinese adult healthy participants.The research period is 7 days in total.
- Trial name
- NCT07457203
- Testing
- Buagafuran, Voriconazole
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Beijing Union Pharmaceutical Factory Ltd
Risk Factors, Polypharmacy
Telecommunication Technology-based Online Survey
The aim of this study is to identify and assess new health-associated risk factors, including clinical-pharmacological risk factors. The cohort is built using telecommunication approaches.
- Conditions
- Risk Factors, Polypharmacy, Drug Interactions, Self Medication
- Trial name
- NCT06159699
- Testing
- Online Survey, Genetic Testing
- Where
- Russia
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Diabetes Mellitus, Type 2, End Stage Renal Disease
Drug Interaction Potential of Pro-Inflammatory Conditions
Pro-inflammatory cytokines, which are elevated in pro-inflammatory disease states (e.g., type II diabetes mellitus [T2DM], irritable bowel diseases [IBD], and end stage renal disease [ESRD]) have been shown to inhibit hepatic…
- Conditions
- Diabetes Mellitus, Type 2, End Stage Renal Disease, Irritable Bowel Syndrome
- Trial name
- DIPPIC (NCT07360938)
- Testing
- None (Observational)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Indiana University
Drug Drug Interaction (DDI), Pharmacokinetics and Pharmacodynamics
Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity
This is a Phase I, open-label, two-cohort study designed to evaluate the drug-drug interaction potential of multiple-dose UBT251 Injection in adult participants with overweight or obesity.
- Trial name
- NCT07785934
- Testing
- UBT251, Metformin hydrochloride, Warfarin Sodium
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Cancer (Solid Tumors), Interaction Drug Food
Dietary Supplements Among Cancer Patients: Tolerance, Impact on Medications, and Potential Drug Interactions
The goal of this observational study is to To assess the prevalence and patterns of dietary supplement use among patients with cancer and to analyze the impact of these supplements in the context of anticancer medical treatments…
- Trial name
- Dietary Supple (NCT07670234)
- Testing
- Dietary Supplement Use Assessment
- Where
- Morocco
- Volunteers
- 1,000 people
- Sponsor
- Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI)
Healthy Adult Participants
A Phase 1 Multiple Dose Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, Drug-Drug Interactions, and Pharmacokinetics of TBD11
This is a Phase 1, randomized, double-blind, placebo-controlled, multiple dose trial of TBD11 in healthy adults. It includes a dedicated open-label cohort in which TBD11 will be administered as a single dose with either a strong…
- Trial name
- NCT07883226
- Testing
- TBD11 (300 mg), Itraconazole (200 mg), Rifampicin 600mg
- Where
- South Africa
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Gates Medical Research Institute
Healthy Adult Participants
A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395
This study will enroll healthy participants to evaluate whether BGB-43395 interacts with other drugs, including midazolam, celecoxib, dabigatran, and rosuvastatin.
- Trial name
- NCT07820891
- Testing
- BGB-43395, Midazolam, Celecoxib
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- BeOne Medicines
Drug Drug Interaction
KF2025#1 Trial: Ketamine, Cannabidiol and Cobicistat Interaction Study
Ketamine is a dissociative anesthetic developed approximately 60 years ago. Both ketamine and its isomer, esketamine, have been used for over 20 years in the treatment of treatment-resistant depression.
- Trial name
- KF2025#1 (NCT07462559)
- Testing
- Ketamine 10 mg/ml oral solution, UK special, Cobisistat Tybost 150 mg, Cannabidiol Epidyolex 100 mg/ml
- Where
- Finland
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Healthy Volunteers
A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy Participants
The primary purpose of this study is to assess potential drug-drug interactions of E2086 when coadministered orally with Itraconazole, Carbamazepine, Midazolam, Dextromethorphan, Bupropion, or Combined Oral Contraceptives in…
- Trial name
- NCT07766369
- Testing
- E2086
- Where
- United States
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Heart Failure With Reduced Ejection Fraction
Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure
An increasing number of guideline-directed medical therapies (GDMT) have been developed for patients with chronic heart failure with reduced ejection fraction (HFrEF).
- Trial name
- IICAPTAIN-HF (NCT06526988)
- Testing
- EPIC-HF Patient-facing Tool, PROMPT-HF Clinician-facing Alert
- Where
- 5 sites in United States
- Volunteers
- 2,200 people
- Sponsor
- University of Colorado, Denver
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.
The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-986521 following single and multiple ascending doses of BMS-986521 in healthy adult participants, and to evaluate potential food effects on…
- Trial name
- NCT07283263
- Testing
- BMS-985521
- Where
- United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy Participants
A Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy Participants
The purpose of this study is to assess the effect of multiple doses of phenytoin, a strong cytochrome P450 (CYP)3A4 inducer, and itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetic (PK) profile of DAK539 (hereafter…
- Trial name
- NCT07783503
- Testing
- Pelabresib, Phenytoin, Itraconazole
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
NSCLC
An Open-label, Fixed-sequence Phase I Clinical Trial to Evaluate the Effect of HS-10504 on the Pharmacokinetics of Midazolam in Patients With Non-small Cell Lung Cancer
This is an open-label, fixed-sequence Phase I clinical trial to evaluate the effect of HS-10504 on the pharmacokinetics of midazolam (CYP3A4 substrate) in patients with EGFR mutation-positive locally advanced or metastatic…
- Trial name
- NCT07685041
- Testing
- HS-10504； midazolam
- Volunteers
- 24 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.